Quercetin Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells

BACKGROUND: Molecular targeted therapies play a crucial role in the management of hepatocellular carcinoma (HCC). Lenvatinib is a standard targeted agent for advanced HCC, while quercetin has emerged as a promising natural compound with anti-HCC potential. This study investigates the combined effect of quercetin and lenvatinib on HCC. METHODS: experiments were conducted to validate the anti-tumor efficacy of the combination treatment. RESULTS: < 0.01) and a Combination Index (CDI) of 0.753. CONCLUSION: Quercetin significantly enhances the anti-tumor efficacy of lenvatinib, likely through synergistic inhibition of PTK2 expression.